Advantages of switch to premixed insulin degludec/aspart in patients with type 2 diabetes mellitus who have not achieved an optimal control with previous insulin therapy

Insulin degludec/aspart (IDeg/Asp) is the first soluble combination of the ultralong-acting human insulin analogue degludec (70%) and the fast-acting prandial human insulin analogue aspart (30%) in one injection. The unique pharmacodynamic profile of IDeg/Asp provides a stable effect of basal insulin (>24 hours), as well as effective prandial control, which does not affect on the basal effect. In patients with type 2 diabetes mellitus, the use of IDeg/Asp once and twice a day provides effective glycemic control with a lower risk of overall and nocturnal hypoglycemia compared to conventional premix and basal-bolus insulin therapy. Furthermore, when required patients can flexible change the injection time of IDeg/Asp compared with the conventional premix insulins. In patients previously received insulin therapy, the switch to IDeg/Asp is a simple helpful choice of optimization and intensification of insulin therapy, which allows to maintain a more stable glucose level during the day, to achieve individual glycemic target without increasing the hypoglycemia risk and adverse weight gain, and also is a well-tolerated. These clinical advantages give possibility to recommend IDeg/Asp as a simple and safe strategy of insulin therapy, including in patients previously received insulin but did not achieve glycemic control.

type 2 diabetes mellitus, insulin, insulin therapy, insulin degludec/aspart